Frontlight ResearchEarly access
WithdrawnEarly phase 1
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Key facts
- Who runs it
- Weill Medical College of Cornell University
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- Dec 2021
- Ended
- Jun 2024
- Type of study
- Interventional
- Treatments tested
- Selinexor
- Dexamethasone
- Record updated
- 17 November 2022
- Why it stopped
- Funding withdrawn
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Diagnosis of primary AL amyloidosis
- Relapsed and/or refractory AL amyloidosis
- Measurable disease
- Male or female patients 18 years or older
- Able to give voluntary written consent
- Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2
- Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3
- Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
- Calculated creatinine clearance ≥ 30 mL/min
Who cannot take part
- Prior exposure to Selinexor
- Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
- Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy
- Major surgery within 14 days before enrollment
- Radiotherapy within 14 days before enrollment
- Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort
- Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Participation in another clinical trials involving investigational agents within 30 days of starting this trial
- Clinically significant cardiac disease
- Severe obstructive airway disease
- Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
- Serious medical or psychiatric illness
- GI disease or GI procedure that could interfere with the oral absorption or tolerance including difficulty swallowing
- Female patients who are lactating or have a positive serum pregnancy test during the screening period
- Non-AL amyloidosis
- Clinically overt myeloma
- Peripheral neuropathy (grade 2 with pain or grade 3 or higher)
Where in United States
- Weill Cornell Medicine - Multiple Myeloma CenterNew York, United States
About the trial
What the trial wants to find out
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
The group in the trial
- selinexor/ dexamethasone (Sd)Treatment being tested
Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity Dexamethasone • 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23
Treatment: Selinexor and Dexamethasone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 November 2022